Janus Henderson Group PLC lessened its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 17.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 256,447 shares of the company's stock after selling 52,871 shares during the quarter. Janus Henderson Group PLC's holdings in Takeda Pharmaceutical were worth $3,647,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. HighTower Advisors LLC grew its position in Takeda Pharmaceutical by 199.5% during the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company's stock worth $1,744,000 after buying an additional 81,653 shares during the period. Centiva Capital LP acquired a new stake in shares of Takeda Pharmaceutical in the 3rd quarter worth approximately $265,000. Erste Asset Management GmbH purchased a new position in Takeda Pharmaceutical in the 3rd quarter valued at approximately $52,000. Verition Fund Management LLC purchased a new position in Takeda Pharmaceutical in the 3rd quarter valued at approximately $1,533,000. Finally, Hantz Financial Services Inc. raised its holdings in Takeda Pharmaceutical by 3.2% during the third quarter. Hantz Financial Services Inc. now owns 226,685 shares of the company's stock worth $3,223,000 after purchasing an additional 6,967 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.
Takeda Pharmaceutical Price Performance
Takeda Pharmaceutical stock traded down $0.11 during trading hours on Thursday, hitting $13.45. The stock had a trading volume of 1,738,029 shares, compared to its average volume of 1,837,175. The stock has a market capitalization of $42.80 billion, a price-to-earnings ratio of 23.19, a PEG ratio of 0.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The stock's fifty day moving average is $13.84 and its two-hundred day moving average is $13.87.
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
